Esophageal cancer is the sixth most common cause of cancer deaths worldwide. Adenocarcinoma is more common in North America and Western European countries, originating mostly in the lower third of the esophagus, which often involves the esophagogastric junction (EGJ). Recent randomized trials have shown that the addition of preoperative chemoradiation or perioperative chemotherapy to surgery significantly improves survival in patients with resectable cancer. Targeted therapies with trastuzumab and ramucirumab have produced encouraging results in the treatment of advanced or metastatic EGJ adenocarcinomas. Multidisciplinary team management is essential for patients with esophageal and EGJ cancers. This portion of the NCCN Guidelines for Esophageal and EGJ Cancers discusses management of locally advanced adenocarcinoma of the esophagus and EGJ.

  • 1.

    JemalABrayFCenterMM. Global cancer statistics. CA Cancer J Clin2011;61:6990.

  • 2.

    SiegelRMaJZouZJemalA. Cancer statistics, 2014. CA Cancer J Clin2014;64:929.

  • 3.

    CorleyDABufflerPA. Oesophageal and gastric cardia adenocarcinomas: analysis of regional variation using the Cancer Incidence in Five Continents database. Int J Epidemiol2001;30:14151425.

    • Search Google Scholar
    • Export Citation
  • 4.

    PickensAOrringerMB. Geographical distribution and racial disparity in esophageal cancer. Ann Thorac Surg2003;76:S13671369.

  • 5.

    SiewertJRKatjaO. Are squamous and adenocarcinomas of the esophagus the same disease?Semin Radiat Oncol2007;17:3844.

  • 6.

    BrownLMDevesaSSChowWH. Incidence of adenocarcinoma of the esophagus among white americans by sex, stage, and age. J Natl Cancer Inst2008;100:11841187.

    • Search Google Scholar
    • Export Citation
  • 7.

    SiewertJRSteinHJFeithM. Histologic tumor type is an independent prognostic parameter in esophageal cancer: lessons from more than 1,000 consecutive resections at a single center in the Western world. Ann Surg2001;234:360367.

    • Search Google Scholar
    • Export Citation
  • 8.

    EdgeSBByrdDRComptonCC. AJCC Cancer Staging Manual.7th edition. New York, NY: Springer; 2010.

  • 9.

    RiceTWRuschVWApperson-HansenC. Worldwide esophageal cancer collaboration. Dis Esophagus2009;22:18.

  • 10.

    KimTJKimHYLeeKWKimMS. Multimodality assessment of esophageal cancer: preoperative staging and monitoring of response to therapy. Radiographics2009;29:403421.

    • Search Google Scholar
    • Export Citation
  • 11.

    SiewertJR. Carcinoma of the cardia: carcinoma of the gastroesophageal junction classification, pathology, and extent of resection. Dis Esophagus1996;9:173182.

    • Search Google Scholar
    • Export Citation
  • 12.

    SiewertJRFeithMWernerMSteinHJ. Adenocarcinoma of the esophagogastric junction: results of surgical therapy based on anatomical/topographic classification in 1,002 consecutive patients. Ann Surg2000;232:353361.

    • Search Google Scholar
    • Export Citation
  • 13.

    HechtmanJFPolydoridesAD. HER2/neu gene amplification and protein overexpression in gastric and gastroesophageal junction adenocarcinoma: a review of histopathology, diagnostic testing, and clinical implications. Arch Pathol Lab Med2012;136:691697.

    • Search Google Scholar
    • Export Citation
  • 14.

    DreilichMWandersABrattstromD. HER-2 overexpression (3+) in patients with squamous cell esophageal carcinoma correlates with poorer survival. Dis Esophagus2006;19:224231.

    • Search Google Scholar
    • Export Citation
  • 15.

    ReicheltUDuesedauPTsourlakisMC. Frequent homogeneous HER-2 amplification in primary and metastatic adenocarcinoma of the esophagus. Mod Pathol2007;20:120129.

    • Search Google Scholar
    • Export Citation
  • 16.

    SchoppmannSFJeschBFriedrichJ. Expression of Her-2 in carcinomas of the esophagus. Am J Surg Pathol2010;34:18681873.

  • 17.

    MoelansCBvan DiestPJMilneANOfferhausGJ. Her-2/neu testing and therapy in gastroesophageal adenocarcinoma. Patholog Res Int2011;2011:674182.

    • Search Google Scholar
    • Export Citation
  • 18.

    GravalosCJimenoA. HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann Oncol2008;19:15231529.

  • 19.

    TannerMHollmenMJunttilaTT. Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann Oncol2005;16:273278.

    • Search Google Scholar
    • Export Citation
  • 20.

    BangYChungHXuJ. Pathological features of advanced gastric cancer (GC): relationship to human epidermal growth factor receptor 2 (HER2) positivity in the global screening programme of the ToGA trial [abstract]. J Clin Oncol2009;27(Suppl 15):Abstract 4556.

    • Search Google Scholar
    • Export Citation
  • 21.

    HofmannMStossOShiD. Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology2008;52:797805.

    • Search Google Scholar
    • Export Citation
  • 22.

    RuschoffJDietelMBarettonG. HER2 diagnostics in gastric cancer-guideline validation and development of standardized immunohistochemical testing. Virchows Arch2010;457:299307.

    • Search Google Scholar
    • Export Citation
  • 23.

    BangYJVan CutsemEFeyereislovaA. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet2010;376:687697.

    • Search Google Scholar
    • Export Citation
  • 24.

    Barros-SilvaJDLeitaoDAfonsoL. Association of ERBB2 gene status with histopathological parameters and disease-specific survival in gastric carcinoma patients. Br J Cancer2009;100:487493.

    • Search Google Scholar
    • Export Citation
  • 25.

    van HagenPHulshofMCvan LanschotJJ. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med2012;366:20742084.

    • Search Google Scholar
    • Export Citation
  • 26.

    CunninghamDAllumWHStenningSP. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med2006;355:1120.

    • Search Google Scholar
    • Export Citation
  • 27.

    SteyerbergEWNevilleBAKoppertLB. Surgical mortality in patients with esophageal cancer: development and validation of a simple risk score. J Clin Oncol2006;24:42774284.

    • Search Google Scholar
    • Export Citation
  • 28.

    KrasnaMJReedCEJaklitschMT. Thoracoscopic staging of esophageal cancer: a prospective, multiinstitutional trial. Cancer and Leukemia Group B Thoracic Surgeons. Ann Thorac Surg1995;60:13371340.

    • Search Google Scholar
    • Export Citation
  • 29.

    BirkmeyerJDSiewersAEFinlaysonEV. Hospital volume and surgical mortality in the United States. N Engl J Med2002;346:11281137.

  • 30.

    SwisherSGWynnPPutnamJB. Salvage esophagectomy for recurrent tumors after definitive chemotherapy and radiotherapy. J Thorac Cardiovasc Surg2002;123:175183.

    • Search Google Scholar
    • Export Citation
  • 31.

    RuschVW. Are cancers of the esophagus, gastroesophageal junction, and cardia one disease, two, or several?Semin Oncol2004;31:444449.

    • Search Google Scholar
    • Export Citation
  • 32.

    SiewertJRSteinHJFeithM. Adenocarcinoma of the esophagogastric junction. Scand J Surg2006;95:260269.

  • 33.

    de GraafGWAyantundeAAParsonsSL. The role of staging laparoscopy in oesophagogastric cancers. Eur J Surg Oncol2007;33:988992.

  • 34.

    NathJMoorthyKTaniereP. Peritoneal lavage cytology in patients with oesophagogastric adenocarcinoma. Br J Surg2008;95:721726.

  • 35.

    GrothSSVirnigBAWhitsonBA. Determination of the minimum number of lymph nodes to examine to maximize survival in patients with esophageal carcinoma: data from the Surveillance Epidemiology and End Results database. J Thorac Cardiovasc Surg2010;139:612620.

    • Search Google Scholar
    • Export Citation
  • 36.

    PeyreCGHagenJADeMeesterSR. Predicting systemic disease in patients with esophageal cancer after esophagectomy: a multinational study on the significance of the number of involved lymph nodes. Ann Surg2008;248:979985.

    • Search Google Scholar
    • Export Citation
  • 37.

    RizkNPIshwaranHRiceTW. Optimum lymphadenectomy for esophageal cancer. Ann Surg2010;251:4650.

  • 38.

    KleinbergLForastiereAA. Chemoradiation in the management of esophageal cancer. J Clin Oncol2007;25:41104117.

  • 39.

    HerskovicAMartzKal-SarrafM. Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med1992;326:15931598.

    • Search Google Scholar
    • Export Citation
  • 40.

    CooperJSGuoMDHerskovicA. Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group. JAMA1999;281:16231627.

    • Search Google Scholar
    • Export Citation
  • 41.

    MinskyBDPajakTFGinsbergRJ. INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. J Clin Oncol2002;20:11671174.

    • Search Google Scholar
    • Export Citation
  • 42.

    LiQQLiuMZHuYH. Definitive concomitant chemoradiotherapy with docetaxel and cisplatin in squamous esophageal carcinoma. Dis Esophagus2010;23:253259.

    • Search Google Scholar
    • Export Citation
  • 43.

    RuppertBNWatkinsJMShiraiK. Cisplatin/Irinotecan versus carboplatin/paclitaxel as definitive chemoradiotherapy for locoregionally advanced esophageal cancer. Am J Clin Oncol2010;33:346352.

    • Search Google Scholar
    • Export Citation
  • 44.

    MeertenEVvan RijCTesselaarME. Definitive concurrent chemoradiation (CRT) with weekly paclitaxel and carboplatin for patients (pts) with irresectable esophageal cancer: a phase II study [abstract]. J Clin Oncol2010;28(Suppl 15):Abstract e14508.

    • Search Google Scholar
    • Export Citation
  • 45.

    ConroyTGalaisMPRaoulJL. Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5/ACCORD17): final results of a randomised, phase 2/3 trial. Lancet Oncol2014;15:305314.

    • Search Google Scholar
    • Export Citation
  • 46.

    IyerRWilkinsonNDemmyTJavleM. Controversies in the multimodality management of locally advanced esophageal cancer: evidence-based review of surgery alone and combined-modality therapy. Ann Surg Oncol2004;11:665673.

    • Search Google Scholar
    • Export Citation
  • 47.

    UrschelJDVasanH. A meta-analysis of randomized controlled trials that compared neoadjuvant chemoradiation and surgery to surgery alone for resectable esophageal cancer. Am J Surg2003;185:538543.

    • Search Google Scholar
    • Export Citation
  • 48.

    FioricaFDi BonaDSchepisF. Preoperative chemoradiotherapy for oesophageal cancer: a systematic review and meta-analysis. Gut2004;53:925930.

    • Search Google Scholar
    • Export Citation
  • 49.

    SjoquistKMBurmeisterBHSmithersBM. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncol2011;12:681692.

    • Search Google Scholar
    • Export Citation
  • 50.

    SwisherSGHofstetterWKomakiR. Improved long-term outcome with chemoradiotherapy strategies in esophageal cancer. Ann Thorac Surg2010;90:892898; discussion 898-899.

    • Search Google Scholar
    • Export Citation
  • 51.

    CenPCorreaAMLeJH. Adenocarcinoma of the lower esophagus with Barrett’s esophagus or without Barrett’s esophagus: differences in patients’ survival after preoperative chemoradiation. Dis Esophagus2009;22:3241.

    • Search Google Scholar
    • Export Citation
  • 52.

    WalshTNNoonanNHollywoodD. A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med1996;335:462467.

    • Search Google Scholar
    • Export Citation
  • 53.

    BossetJFGignouxMTribouletJP. Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus. N Engl J Med1997;337:161167.

    • Search Google Scholar
    • Export Citation
  • 54.

    UrbaSGOrringerMBTurrisiA. Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. J Clin Oncol2001;19:305313.

    • Search Google Scholar
    • Export Citation
  • 55.

    BainsMSStojadinovicAMinskyB. A phase II trial of preoperative combined-modality therapy for localized esophageal carcinoma: initial results. J Thorac Cardiovasc Surg2002;124:270277.

    • Search Google Scholar
    • Export Citation
  • 56.

    KaklamanosIGWalkerGRFerryK. Neoadjuvant treatment for resectable cancer of the esophagus and the gastroesophageal junction: a meta-analysis of randomized clinical trials. Ann Surg Oncol2003;10:754761.

    • Search Google Scholar
    • Export Citation
  • 57.

    BurmeisterBHSmithersBMGebskiV. Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial. Lancet Oncol2005;6:659668.

    • Search Google Scholar
    • Export Citation
  • 58.

    MarietteCDahanLMornexF. Surgery alone versus chemoradiotherapy followed by surgery for stage I and II esophageal cancer: final analysis of randomized controlled phase III trial FFCD 9901. J Clin Oncol2014;32:24162422.

    • Search Google Scholar
    • Export Citation
  • 59.

    OppedijkVvan der GaastAvan LanschotJJ. Patterns of recurrence after surgery alone versus preoperative chemoradiotherapy and surgery in the CROSS trials. J Clin Oncol2014;32:385391.

    • Search Google Scholar
    • Export Citation
  • 60.

    TepperJKrasnaMJNiedzwieckiD. Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol2008;26:10861092.

    • Search Google Scholar
    • Export Citation
  • 61.

    BurmeisterBHThomasJMBurmeisterEA. Is concurrent radiation therapy required in patients receiving preoperative chemotherapy for adenocarcinoma of the oesophagus? A randomised phase II trial. Eur J Cancer2011;47:354360.

    • Search Google Scholar
    • Export Citation
  • 62.

    MacdonaldJSSmalleySRBenedettiJ. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med2001;345:725730.

    • Search Google Scholar
    • Export Citation
  • 63.

    SmalleySRBenedettiJKHallerDG. Updated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection. J Clin Oncol2012;30:23272333.

    • Search Google Scholar
    • Export Citation
  • 64.

    BedardELInculetRIMalthanerRA. The role of surgery and postoperative chemoradiation therapy in patients with lymph node positive esophageal carcinoma. Cancer2001;91:24232430.

    • Search Google Scholar
    • Export Citation
  • 65.

    RiceTWAdelsteinDJChidelMA. Benefit of postoperative adjuvant chemoradiotherapy in locoregionally advanced esophageal carcinoma. J Thorac Cardiovasc Surg2003;126:15901596.

    • Search Google Scholar
    • Export Citation
  • 66.

    KofoedSCMuhicABaeksgaardL. Survival after adjuvant chemoradiotherapy or surgery alone in resectable adenocarcinoma at the gastro-esophageal junction. Scand J Surg2012;101:2631.

    • Search Google Scholar
    • Export Citation
  • 67.

    AdelsteinDJRiceTWRybickiLA. Mature results from a phase II trial of postoperative concurrent chemoradiotherapy for poor prognosis cancer of the esophagus and gastroesophageal junction. J Thorac Oncol2009;4:12641269.

    • Search Google Scholar
    • Export Citation
  • 68.

    FuchsCSTepperJENiedzwieckiD. Postoperative adjuvant chemoradiation for gastric or gastroesophageal junction (GEJ) adenocarcinoma using epirubicin, cisplatin, and infusional (CI) 5-FU (ECF) before and after CI 5-FU and radiotherapy (CRT) compared with bolus 5-FU/LV before and after CRT: Intergroup trial CALGB 80101[abstract]. J Clin Oncol2011;29(Suppl 15):Abstract 4003.

    • Search Google Scholar
    • Export Citation
  • 69.

    KelsenDPGinsbergRPajakTF. Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. N Engl J Med1998;339:19791984.

    • Search Google Scholar
    • Export Citation
  • 70.

    KelsenDPWinterKAGundersonLL. Long-term results of RTOG trial 8911 (USA Intergroup 113): a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer. J Clin Oncol2007;25:37193725.

    • Search Google Scholar
    • Export Citation
  • 71.

    Medical Research Council Oesophageal Cancer Working Group. Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial. Lancet2002;359:17271733.

    • Search Google Scholar
    • Export Citation
  • 72.

    AllumWHStenningSPBancewiczJ. Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer. J Clin Oncol2009;27:50625067.

    • Search Google Scholar
    • Export Citation
  • 73.

    BoonstraJJKokTCWijnhovenBP. Chemotherapy followed by surgery versus surgery alone in patients with resectable oesophageal squamous cell carcinoma: long-term results of a randomized controlled trial. BMC Cancer2011;11:181.

    • Search Google Scholar
    • Export Citation
  • 74.

    ThirionPGMichielsSLe MaitreA. Individual patient data-based meta-analysis assessing pre-operative chemotherapy in resectable oesophageal carcinoma [abstract]. J Clin Oncol2007;25(Suppl 18):Abstract 4512.

    • Search Google Scholar
    • Export Citation
  • 75.

    YchouMBoigeVPignonJP. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol2011;29:17151721.

    • Search Google Scholar
    • Export Citation
  • 76.

    LeichmanLBerryBT. Experience with cisplatin in treatment regimens for esophageal cancer. Semin Oncol1991;18:6472.

  • 77.

    Muhr-WilkenshoffFHinkelbeinWOhnesorgeI. A pilot study of irinotecan (CPT-11) as single-agent therapy in patients with locally advanced or metastatic esophageal carcinoma. Int J Colorectal Dis2003;18:330334.

    • Search Google Scholar
    • Export Citation
  • 78.

    EnzingerPCKulkeMHClarkJW. A phase II trial of irinotecan in patients with previously untreated advanced esophageal and gastric adenocarcinoma. Dig Dis Sci2005;50:22182223.

    • Search Google Scholar
    • Export Citation
  • 79.

    BurkartCBokemeyerCKlumpB. A phase II trial of weekly irinotecan in cisplatin-refractory esophageal cancer. Anticancer Res2007;27:28452848.

    • Search Google Scholar
    • Export Citation
  • 80.

    MuroKHamaguchiTOhtsuA. A phase II study of single-agent docetaxel in patients with metastatic esophageal cancer. Ann Oncol2004;15:955959.

    • Search Google Scholar
    • Export Citation
  • 81.

    AlbertssonMJohanssonBFrieslandS. Phase II studies on docetaxel alone every third week, or weekly in combination with gemcitabine in patients with primary locally advanced, metastatic, or recurrent esophageal cancer. Med Oncol2007;24:407412.

    • Search Google Scholar
    • Export Citation
  • 82.

    AjaniJAIlsonDHDaughertyK. Activity of taxol in patients with squamous cell carcinoma and adenocarcinoma of the esophagus. J Natl Cancer Inst1994;86:10861091.

    • Search Google Scholar
    • Export Citation
  • 83.

    IlsonDHWadleighRGLeichmanLPKelsenDP. Paclitaxel given by a weekly 1-h infusion in advanced esophageal cancer. Ann Oncol2007;18:898902.

    • Search Google Scholar
    • Export Citation
  • 84.

    HarstrickABokemeyerCPreusserP. Phase II study of single-agent etoposide in patients with metastatic squamous-cell carcinoma of the esophagus. Cancer Chemother Pharmacol1992;29:321322.

    • Search Google Scholar
    • Export Citation
  • 85.

    IlsonDHAjaniJBhallaK. Phase II trial of paclitaxel, fluorouracil, and cisplatin in patients with advanced carcinoma of the esophagus. J Clin Oncol1998;16:18261834.

    • Search Google Scholar
    • Export Citation
  • 86.

    PetraschSWeltAReinacherA. Chemotherapy with cisplatin and paclitaxel in patients with locally advanced, recurrent or metastatic oesophageal cancer. Br J Cancer1998;78:511514.

    • Search Google Scholar
    • Export Citation
  • 87.

    IlsonDHForastiereAArquetteM. A phase II trial of paclitaxel and cisplatin in patients with advanced carcinoma of the esophagus. Cancer J2000;6:316323.

    • Search Google Scholar
    • Export Citation
  • 88.

    AjaniJAFodorMBTjulandinSA. Phase II multi-institutional randomized trial of docetaxel plus cisplatin with or without fluorouracil in patients with untreated, advanced gastric, or gastroesophageal adenocarcinoma. J Clin Oncol2005;23:56605667.

    • Search Google Scholar
    • Export Citation
  • 89.

    Van CutsemEMoiseyenkoVMTjulandinS. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol2006;24:49914997.

    • Search Google Scholar
    • Export Citation
  • 90.

    KimJYDoYRParkKU. A multi-center phase II study of docetaxel plus cisplatin as first-line therapy in patients with metastatic squamous cell esophageal cancer. Cancer Chemother Pharmacol2010;66:3136.

    • Search Google Scholar
    • Export Citation
  • 91.

    Al-BatranSEHartmannJTHofheinzR. Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie. Ann Oncol2008;19:18821887.

    • Search Google Scholar
    • Export Citation
  • 92.

    ShankaranVMulcahyMFHochsterHS. Docetaxel, oxaliplatin, and 5-fluorouracil for the treatment of metastatic or unresectable gastric or gastroesophageal junction (GEJ) adenocarcinomas: preliminary results of a phase II study [abstract]. Presented at 2009 ASCO Gastrointestinal Cancers Symposium; January 15–17, 2009; San Francisco, California. Abstract 47.

    • Search Google Scholar
    • Export Citation
  • 93.

    OvermanMJKazmiSMJhambJ. Weekly docetaxel, cisplatin, and 5-fluorouracil as initial therapy for patients with advanced gastric and esophageal cancer. Cancer2010;116:14461453.

    • Search Google Scholar
    • Export Citation
  • 94.

    TebbuttNCCumminsMMSourjinaT. Randomised, noncomparative phase II study of weekly docetaxel with cisplatin and 5-fluorouracil or with capecitabine in oesophagogastric cancer: the AGITG ATTAX trial. Br J Cancer2010;102:475481.

    • Search Google Scholar
    • Export Citation
  • 95.

    SteinAArnoldDThuss-PatiencePC. Docetaxel, oxaliplatin and capecitabine (TEX regimen) in patients with metastatic gastric or gastroesophageal cancer: results of a multicenter phase I/II study. Acta Oncol2014;53:392398.

    • Search Google Scholar
    • Export Citation
  • 96.

    CunninghamDStarlingNRaoS. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med2008;358:3646.

  • 97.

    IlsonDH. Phase II trial of weekly irinotecan/cisplatin in advanced esophageal cancer. Oncology (Williston Park)2004;18:2225.

  • 98.

    DankMZaluskiJBaroneC. Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction. Ann Oncol2008;19:14501457.

    • Search Google Scholar
    • Export Citation
  • 99.

    WolffKWeinAReulbachU. Weekly high-dose 5-fluorouracil as a 24-h infusion and sodium folinic acid (AIO regimen) plus irinotecan in patients with locally advanced nonresectable and metastatic adenocarcinoma or squamous cell carcinoma of the oesophagus: a phase II trial. Anticancer Drugs2009;20:165173.

    • Search Google Scholar
    • Export Citation
  • 100.

    BurtnessBGibsonMEglestonB. Phase II trial of docetaxelirinotecan combination in advanced esophageal cancer. Ann Oncol2009;20:12421248.

    • Search Google Scholar
    • Export Citation
  • 101.

    LustbergMBBekaii-SaabTYoungD. Phase II randomized study of two regimens of sequentially administered mitomycin C and irinotecan in patients with unresectable esophageal and gastroesophageal adenocarcinoma. J Thorac Oncol2010;5:713718.

    • Search Google Scholar
    • Export Citation
  • 102.

    MoehlerMKanzlerSGeisslerM. A randomized multicenter phase II study comparing capecitabine with irinotecan or cisplatin in metastatic adenocarcinoma of the stomach or esophagogastric junction. Ann Oncol2010;21:7177.

    • Search Google Scholar
    • Export Citation
  • 103.

    GuimbaudRLouvetCRiesP. Prospective, randomized, multicenter, phase III study of fluorouracil, leucovorin, and irinotecan versus epirubicin, cisplatin, and capecitabine in advanced gastric adenocarcinoma: a French Intergroup (Federation Francophone de Cancerologie Digestive, Federation Nationale des Centres de Lutte Contre le Cancer, and Groupe Cooperateur Multidisciplinaire en Oncologie) study. J Clin Oncol2014;32:35203526.

    • Search Google Scholar
    • Export Citation
  • 104.

    AssersohnLBrownGCunninghamD. Phase II study of irinotecan and 5-fluorouracil/leucovorin in patients with primary refractory or relapsed advanced oesophageal and gastric carcinoma. Ann Oncol2004;15:6469.

    • Search Google Scholar
    • Export Citation
  • 105.

    LearyAAssersohnLCunninghamD. A phase II trial evaluating capecitabine and irinotecan as second line treatment in patients with oesophago-gastric cancer who have progressed on, or within 3 months of platinum-based chemotherapy. Cancer Chemother Pharmacol2009;64:455462.

    • Search Google Scholar
    • Export Citation
  • 106.

    MauerAMKrautEHKraussSA. Phase II trial of oxaliplatin, leucovorin and fluorouracil in patients with advanced carcinoma of the esophagus. Ann Oncol2005;16:13201325.

    • Search Google Scholar
    • Export Citation
  • 107.

    Al-BatranSEHartmannJTProbstS. Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol2008;26:14351442.

    • Search Google Scholar
    • Export Citation
  • 108.

    El-RayesBFShieldsAZalupskiM. A phase II study of carboplatin and paclitaxel in esophageal cancer. Ann Oncol2004;15:960965.

  • 109.

    RossPNicolsonMCunninghamD. Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) with epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer. J Clin Oncol2002;20:19962004.

    • Search Google Scholar
    • Export Citation
  • 110.

    UrbaSGChanskyKVanVeldhuizenPJ. Gemcitabine and cisplatin for patients with metastatic or recurrent esophageal carcinoma: a Southwest Oncology Group study. Invest New Drugs2004;22:9197.

    • Search Google Scholar
    • Export Citation
  • 111.

    MillarJScullinPMorrisonA. Phase II study of gemcitabine and cisplatin in locally advanced/metastatic oesophageal cancer. Br J Cancer2005;93:11121116.

    • Search Google Scholar
    • Export Citation
  • 112.

    HomsMYvan der GaastASiersemaPD. Chemotherapy for metastatic carcinoma of the esophagus and gastro-esophageal junction. Cochrane Database Syst Rev2006:CD004063.

    • Search Google Scholar
    • Export Citation
  • 113.

    ShahMASchwartzGK. Treatment of metastatic esophagus and gastric cancer. Semin Oncol2004;31:574587.

  • 114.

    FuchsCSTomasekJYongCJ. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet2014;383:3139.

    • Search Google Scholar
    • Export Citation
  • 115.

    WilkeHMuroKVan CutsemE. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol2014;15:12241235.

    • Search Google Scholar
    • Export Citation
  • 116.

    van WestreenenHLWesterterpMBossuytPM. Systematic review of the staging performance of 18F-fluorodeoxyglucose positron emission tomography in esophageal cancer. J Clin Oncol2004;22:38053812.

    • Search Google Scholar
    • Export Citation
  • 117.

    RosenbaumSStergarHAntochG. Staging and follow-up of gastrointestinal tumors with PET/CT. Abdominal Imaging2006;31:2535.

  • 118.

    MundenRFMacapinlacHAErasmusJJ. Esophageal cancer: the role of integrated CT-PET in initial staging and response assessment after preoperative therapy. J Thorac Imaging2006;21:137145.

    • Search Google Scholar
    • Export Citation
  • 119.

    FlamenPLerutAVan CutsemE. Utility of positron emission tomography for the staging of patients with potentially operable esophageal carcinoma. J Clin Oncol2000;18:32023210.

    • Search Google Scholar
    • Export Citation
  • 120.

    FlamenPLerutTHaustermansK. Position of positron emission tomography and other imaging diagnostic modalities in esophageal cancer. Q J Nucl Med Mol Imaging2004;48:96108.

    • Search Google Scholar
    • Export Citation
  • 121.

    CerfolioRJBryantASOhjaB. The accuracy of endoscopic ultrasonography with fine-needle aspiration, integrated positron emission tomography with computed tomography, and computed tomography in restaging patients with esophageal cancer after neoadjuvant chemoradiotherapy. J Thorac Cardiovasc Surg2005;129:12321241.

    • Search Google Scholar
    • Export Citation
  • 122.

    BlencoweNSWhistanceRNStrongS. Evaluating the role of fluorodeoxyglucose positron emission tomography-computed tomography in multi-disciplinary team recommendations for oesophago-gastric cancer. Br J Cancer2013;109:14451450.

    • Search Google Scholar
    • Export Citation
  • 123.

    DuCZhouYHuangK. Defining a high-risk subgroup of pathological T2N0 gastric cancer by prognostic risk stratification for adjuvant therapy. J Gastrointest Surg2011;15:21532158.

    • Search Google Scholar
    • Export Citation
  • 124.

    Thuss-PatiencePCKretzschmarABichevD. Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer—a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Eur J Cancer2011;47:23062314.

    • Search Google Scholar
    • Export Citation
  • 125.

    FordHERMarshallABridgewaterJA. Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial. Lancet Oncol2014;15:7886.

    • Search Google Scholar
    • Export Citation
  • 126.

    KarnofskyDABurchenalJH. The clinical evaluation of chemotherapeutic agents in cancer. In: MacLeodCM ed. Evaluation of Chemotherapeutic Agents.New York Columbia University Press: New York, NY; 1949:199205.

    • Search Google Scholar
    • Export Citation
  • 127.

    SchagCCHeinrichRLGanzPA. Karnofsky performance status revisited: reliability, validity, and guidelines. J Clin Oncol1984;2:187193.

  • 128.

    OkenMMCreechRHTormeyDC. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol1982;5:649655.

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 507 507 52
PDF Downloads 99 99 8
EPUB Downloads 0 0 0